Farther Finance Advisors LLC Raises Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Farther Finance Advisors LLC increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 461.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,547 shares of the company’s stock after purchasing an additional 2,093 shares during the period. Farther Finance Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $40,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in RDY. EverSource Wealth Advisors LLC grew its stake in shares of Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after acquiring an additional 1,507 shares during the last quarter. POM Investment Strategies LLC boosted its stake in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after purchasing an additional 1,820 shares in the last quarter. Allworth Financial LP grew its position in Dr. Reddy’s Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after purchasing an additional 2,230 shares during the last quarter. Sierra Ocean LLC acquired a new position in Dr. Reddy’s Laboratories during the 4th quarter valued at approximately $43,000. Finally, Independence Bank of Kentucky raised its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after buying an additional 2,220 shares during the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE RDY opened at $13.73 on Monday. The stock has a market cap of $11.46 billion, a price-to-earnings ratio of 21.86 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.50 and a 12 month high of $16.89. The company has a 50 day simple moving average of $13.66 and a two-hundred day simple moving average of $14.68. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RDY. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.